title: The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
abstract: The CHICAGO study (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) tested the hypothesis that pioglitazone would have a beneficial effect for reducing CIMT progression, compared with glimepiride. Treatment with pioglitazone produced improvement in several parameters, such as systolic blood pressure and lipid levels, including a 14% increase in HDL cholesterol, and reduced CIMT progression, compared with glimepiride. However, only the beneficial effect on HDL cholesterol predicted its beneficial effect for reducing CIMT progression. The following review examines data from additional studies evaluating how pioglitazone and HDL levels modify cardiovascular risk.
authors.affiliation: Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA.
authors.forename: Tamar
authors.initials: T
authors.lastname: Polonsky
authors.forename: Theodore
authors.initials: T
authors.lastname: Mazzone
authors.forename: Michael
authors.initials: M
authors.lastname: Davidson
mesh_terms: D002339:Carotid Arteries / Q000187:drug effects; D002641:Chicago; D008076:Cholesterol, HDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000077205:Pioglitazone; D016032:Randomized Controlled Trials as Topic; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use*; D017539:Tunica Intima / Q000187:drug effects*
chemical_list: D008076:Cholesterol, HDL; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; C057619:glimepiride; D000077205:Pioglitazone